Biogen looks beyond Spinraza in SMA with Ionis deal
Roche builds evidence for Evrysdi’s benefits in younger SMA patients
Biogen plans trial of Spinraza in patients not responding to SMA gene therapy
FDA cues up May verdict for Roche’s SMA challenger risdiplam
NHS chief hails SMA drug deal – and was that a swipe at Vertex?
PTC shares soar after SMA drug data impresses market
Biogen sees Spinraza slow down in Q3, bullish on Alzheimer’s chances